CellGenic logo
Provider Login
My Account
Become a Provider
cellgenic_official_logo_black

Ipamorelin: Benefits, Handling, the CJC-1295 Stack, and Quality Standards

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food or cosmetic.

Ipamorelin is classified under the World Anti-Doping Agency’s Prohibited List (Section S2.2.4, Growth Hormone Secretagogues), at all times, for tested athletes.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (a five-amino-acid chain) first characterized in 1998 as a growth hormone secretagogue, a molecule that stimulates the release of GH already stored in the pituitary, rather than signaling the pituitary to synthesize new GH the way a GHRH analog does. Ipamorelin acts as an agonist at the ghrelin receptor (GHS-R1a) on the pituitary gland. What distinguished it from earlier secretagogues in its foundational research was selectivity: at doses far exceeding what was needed to release GH, it did not meaningfully elevate ACTH or cortisol a selectivity profile not previously reported for this class of compound. 

Ipamorelin was later advanced into Phase II/III human clinical trials for postoperative ileus by a pharmaceutical developer; that program did not reach approval, and ipamorelin is now supplied as a research compound.

Benefits and Uses

Available research on ipamorelin centers on its selective effect on the GH axis:
  • GH release with hormonal selectivity. The defining research finding: ipamorelin has been shown to stimulate GH release with potency comparable to older secretagogues, while producing minimal elevation of cortisol, prolactin, or ACTH hormones that older GH secretagogues affect more broadly.
  • IGF-1 signaling. Research has examined ipamorelin’s downstream effect on IGF-1, the hormone through which most of GH’s tissue-level effects, including muscle recovery and tissue repair, are mediated.
  • Pulsatile release preservation. Studies report that ipamorelin preserves the body’s natural pulsatile GH release pattern rather than producing a sustained artificial elevation.
  • Bone and gastrointestinal research. A smaller body of preclinical research has examined ipamorelin’s relationship to bone growth and gastrointestinal motility, reflecting the broader physiological roles of the ghrelin receptor pathway it acts through.
Human data for ipamorelin specifically remains limited relative to its research profile. Most published evidence comes from pharmacokinetic/pharmacodynamic studies and preclinical models rather than large controlled outcome trials.

How It Works

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the body’s own ghrelin, triggering pulsatile GH release from the pituitary. Because it acts through a different receptor system than GHRH analogs (which bind the GHRH receptor), research has examined combining ipamorelin with a GHRH analog to stimulate both pathways simultaneously, producing a larger GH pulse than either pathway alone.

Dosage and Administration

No standardized dosing protocol exists for ipamorelin outside of individual study designs, and any research protocol, route, or dose is determined solely by the licensed researcher or practitioner and their institution.

Published pharmacokinetic research has most frequently used subcutaneous or intravenous administration in both animal and early human studies. This reflects historical study design, not a recommended or current protocol.

For labs converting a professional’s own determined research dose into an accurate reconstitution volume, CellGenic’s calculator tool is open to any visitor, with no account required.

Side Effects and Safety

Ipamorelin’s selectivity gives it a favorable tolerability profile relative to older secretagogues in the published research, largely attributable to its minimal effect on cortisol and prolactin. Reported effects in available human trials have been generally mild. Long-term human safety data remain limited, and theoretical concerns associated with sustained GH elevation, including effects on insulin sensitivity, warrant the same monitoring applied to other GH-axis research. Researchers should establish baseline metabolic and IGF-1 values before and during any protocol.

Quality & Verification Standards

Every CellGenic lot is manufactured under cGMP conditions and undergoes mycoplasma, sterility, identity, and potency testing prior to release. Certificates of Analysis are issued per batch and can be retrieved directly using your batch number.

The CJC-1295 Stack

Ipamorelin is frequently studied and supplied alongside CJC-1295. The two act through independent receptor systems: CJC-1295 signals the pituitary via the GHRH receptor to synthesize and release GH, while ipamorelin triggers release of already-stored GH via the ghrelin receptor and research has examined this combination for a larger, more sustained GH pulse than either produces alone.

Become a Verified Provider

Certificates of Analysis, batch documentation, and pricing are available exclusively to verified physicians, clinic operators, and researchers.

Become a Provider → A CellGenic specialist will follow up within one business day. Once your account is verified, full pricing and Certificates of Analysis unlock automatically.

References:

  1. PubMed: Ipamorelin and growth hormone secretion literature
  2. PubMed: Growth hormone secretagogues and ghrelin receptor pharmacology
  3. FDA: Bulk drug substances used in compounding under Section 503A

FAQ

What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) engineered as a selective growth hormone secretagogue. It acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a) on the anterior pituitary gland, signaling the release of pre-synthesized growth hormone. It is intended strictly for in vitro laboratory experimentation.
Its primary distinguishing characteristic in foundational research is receptor selectivity. Unlike earlier secretagogues like GHRP-6 or GHRP-2, Ipamorelin stimulates GH release without causing significant concurrent elevations in adrenocorticotropic hormone (ACTH), cortisol, or prolactin, even at high experimental doses.

Researchers study this combination because the two peptides activate non-overlapping, complementary signaling pathways:

  • Ipamorelin targets the GHS-R1a (ghrelin) receptor to trigger the acute release of stored growth hormone vesicles.
  • CJC-1295 targets GHRH receptors to promote continuous cellular synthesis of new growth hormone.
No standardized administration protocol exists for research chemicals outside specific experimental designs. Protocol routes, frequencies, and doses must be determined solely by licensed researchers within qualified laboratory parameters. Bodily administration into humans or animals is strictly prohibited by law.
Ipamorelin is an unapproved research chemical and is explicitly banned by the World Anti-Doping Agency (WADA) under Section S2.2.4 for tested athletes. While published studies note favorable hormonal selectivity, long-term human safety profiles remain unestablished, and sustained GH elevation requires monitoring of glucose metabolism and IGF-1 levels.

REGULATORY DISCLAIMER · PEPTIDES

These products are intended for laboratory research use only. They are not drugs, foods, cosmetics, or medical treatments and must not be used for any form of human or animal administration. All information provided is for educational and scientific reference only and the products should be handled exclusively by licensed, qualified professionals. Misbranding, misuse, or mislabeling of these products as therapeutic or consumable substances is strictly prohibited by law.

CellGenic ships exclusively to Mexico, Argentina, Colombia, and Perú under local license. Verified-provider-only platform from CellGenic.

Shopping cart0
There are no products in the cart!
Continue shopping
Cart Gated

Cart is provider-gated. Log in to view.

Provider Login →